The authors suggested that the abnormal expression of NaV1.5 could be associated with the metastatic process in human ovarian cancer and could be used as a therapeutic target in ovarian cancer treatment (Gao et al., 2010). This evidence concerns the gene SCN5A and ovarian carcinoma.